- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05965284
Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
A Prospective, Open-label, Controlled, Single Center Clinical Study of the Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: The basic theme of AAV is relapse and remission. The maintenance therapy of AAV aimed to reduce or prevent relapse is very challenge. Although many medications have been used for the maintenance of AAV, Telitacicept (a BAFF/APRIL dual-target-inhibitor, which has been proved to be effect in treatment of SLE) has not been studied yet. One study tested the efficacy of Belimumab in the maintenance therapy for AAV. When taken Rituximab as remission-induction treatment, no relapse was observed. However, the sample size of this study is small, and the Belimumab, as a BAFF inhibitor, was not been proved to have effect on APRIL.
Many experiences have been accumulated about the efficacy and safety of Telitacicept in Chinese patients with rheumatic diseases. But there is no study to show its effectiveness in the reduction of the relapse of AAV in China. In this study, we add Telitacicept to azathioprine in maintain treatment in AAV patients who receive Rituximab as remission-induction treatment, to compare the relapse rates of Telitacicept combining azathioprine and azathioprine alone in maintenance therapy of AAV.
Objectives: To compare the relapse rates of Telitacicept combining azathioprine and azathioprine alone in maintenance treatment of AAV.
Study Design: This is a prospective, randomized, open-label, control, pilot study.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Yunjiao Yang, M.D.
- Phone Number: +86-13671313079
- Email: yangyunjiao81@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Hanqi Wang, RN
- Phone Number: 86-15810927696
- Email: lijing6515@pumch.cn
-
Contact:
- Yunjiao Yang, M.D.
- Phone Number: 86-13671313079
- Email: yangyunjiao81@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients age 18 to 65 years, both genders can be included.
- Patients who are newly diagnosed or relapsing granulomatosis with polyangiitis or microscopic polyangiitis must fulfill the 2022 ACR/EULAR classification criteria of GPA or MPA.
- Patients who are in complete remission after combined treatment with glucocorticoids and Rituximab. Remission is defined as a Birmingham Vasculitis Activity Score (BVAS version 3) of 0. And the daily dosage of prednisone are no more than 10mg (or equivalent).
- Patients have to be ANCA-positive at diagnosis or during the course of their disease.
Exclusion Criteria:
- Patients with TPMT gene mutation.
- Patients who had been treated with either AZA but relapsed in the past.
- Patients who had been treated with either AZA but had to stop due to adverse events or intolerance.
- Patients who have planned for pregnancy in next 1.5 years.
- Patients with severe liver dysfunction(defined as the 2-folds elevation of normal upper limit or Child grade III), heart failure or ESRD(eGFR<30ml/min).
- Patients with uncontrolled sever hypertension, diabetes, active bacteria or fungal infection;
- Patients with active hepatitis virus infection as well as patients who have active mycobacteria infection;
- Patients who had other autoimmune diseases.
- Patients with malignancy.
- Patients who are not eligible according to the judge of the principal investigators or site investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Azathioprine treatment arm
Patients will be treated with Azathioprine 100mg per day for 12 months combined with prednisone no more than 10mg daily.
The dosage of prednisone is tapered in the study period while sustained remission achieved.
All included patients will be treated with TMPco 2 tablets per day during the study period if not contraindicated or intolerant.
|
All patients included into this study will be treated with Azathioprine tablets 100mg QD for 12 months.
|
Experimental: Telitacicept treatment arm
Patients will be treated with Telitacicept 160mg per week combined with Azathioprine 100mg per day for 12 months combined with prednisone no more than 10mg daily.
The dosage of prednisone is tapered in the study period while sustained remission achieved.
All included patients will be treated with TMPco 2 tablets per day during the study period if not contraindicated or intolerant.
|
All patients included into this study will be treated with Azathioprine tablets 100mg QD for 12 months.
Patient will be treated with Telitacicept (Taiai the commercial name) 160 mg every week subcutaneously for 12 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The time of first relapse during 12 months follow-up of two groups
Time Frame: from inclusion to the end of the study, 12 months in total
|
The time from baseline to first relapse(re-appearance of disease with a BVAS >0) of patients during 12 months follow-up of two groups
|
from inclusion to the end of the study, 12 months in total
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of patients with severe relapse at months 12
Time Frame: from inclusion to the end of the study, 12 months in total
|
The percentage of patients with severe relapse (re-appearance or worsening of disease with a BVAS ≥6 and involvement of at least one major organ, a life-threatening manifestation, or both) at months 12
|
from inclusion to the end of the study, 12 months in total
|
The percentage of patients with moderate relapse at months 12
Time Frame: from inclusion to the end of the study, 12 months in total
|
The percentage of patients with moderate relapse (re-appearance or worsening of disease with a BVAS ≥3 without involvement of major organ or life-threatening manifestation) at months 12
|
from inclusion to the end of the study, 12 months in total
|
The percentage of patients with mild relapse at months 12
Time Frame: from inclusion to the end of the study, 12 months in total
|
The percentage of patients with mild relapse (re-appearance or worsening of disease with a 0 < BVAS < 3 without involvement of major organ or life-threatening manifestation) at months 12
|
from inclusion to the end of the study, 12 months in total
|
The percentage of patients with sustained remission at months 12
Time Frame: from inclusion to the end of the study, 12 months in total
|
The percentage of patients with sustained remission (BVAS =0 without dosage increase of glucocorticoid) at months 12
|
from inclusion to the end of the study, 12 months in total
|
The rate of adverse events
Time Frame: from inclusion to the end of the study, 12 months in total
|
The rate of adverse events and their severity (Severe events were defined as the adverse events of grade 3 or 4, deaths caused by any cause, cancers, side effects that necessitate hospitalization) in both two groups during the study period.
|
from inclusion to the end of the study, 12 months in total
|
The percentage of patients who progress to ESRD
Time Frame: from inclusion to the end of the study, 12 months in total
|
The percentage of patients who progress to ESRD at the end of the study
|
from inclusion to the end of the study, 12 months in total
|
The rate of complication of AAV
Time Frame: from inclusion to the end of the study, 12 months in total
|
The rate of complication of AAV in both treatment groups during 12 months of the study period.
|
from inclusion to the end of the study, 12 months in total
|
Collaborators and Investigators
Investigators
- Principal Investigator: JIng Li, M.D., Peking Unione Mdecial College Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Immune System Diseases
- Autoimmune Diseases
- Skin Diseases, Vascular
- Systemic Vasculitis
- Vasculitis
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Azathioprine
Other Study ID Numbers
- CSTAR-K2374
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ANCA-associated Vasculitis
-
University Hospital, Strasbourg, FranceRecruiting
-
Xiangya Hospital of Central South UniversityThe Third Xiangya Hospital of Central South University; Hunan Provincial People... and other collaboratorsRecruiting
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedANCA-Associated VasculitisUnited Kingdom
-
Chinese SLE Treatment And Research GroupThe First Affiliated Hospital of Anhui Medical University; Shanghai Zhongshan... and other collaboratorsRecruitingANCA Associated Vasculitis | Maintenance TherapyChina
-
University Hospital Birmingham NHS Foundation TrustMerck Sharp & Dohme LLCRecruitingANCA Associated VasculitisUnited Kingdom
-
University Hospital, BrestNot yet recruitingOccupational Diseases | ANCA Associated Vasculitis | Environmental ExposureFrance
-
Shanghai Zhongshan HospitalCompletedDrug Use | ANCA Associated Vasculitis | JAK-STAT Pathway DeregulationChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingANCA Associated VasculitisChina
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)SuspendedANCA Associated VasculitisUnited States
-
Chinese SLE Treatment And Research GroupPeking Union Medical College HospitalRecruitingANCA Associated VasculitisChina
Clinical Trials on Azathioprine
-
National Institute of Diabetes and Digestive and...Prometheus LaboratoriesTerminated
-
Nova Laboratories LimitedSyne Qua Non Limited; Medicines Evaluation Unit Ltd; Alderley Analytical Ltd; Black... and other collaboratorsCompletedTherapeutic EquivalencyUnited Kingdom
-
Australian and New Zealand Intensive Care Research...Recruiting
-
Merck Sharp & Dohme LLCTerminated
-
Bristol-Myers SquibbTerminated
-
First Affiliated Hospital of Guangxi Medical UniversityCompletedNMO Spectrum Disorder | Azathioprine Adverse ReactionChina
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityUnknown
-
University Medical Center GroningenZonMw: The Netherlands Organisation for Health Research and Development; Dutch... and other collaboratorsTerminated
-
Ain Shams UniversityCapital Birth CenterCompletedIn Vitro Fertilization | Recurrent Implantation Failure | Intracytoplsmic Sperm InjectionEgypt
-
Bristol-Myers SquibbTerminated